Jake R. Nunn's most recent trade in Zenas Biopharma Inc. was a trade of 63,158 Common Stock done at an average price of $19 . Disclosure was reported to the exchange on Oct. 9, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Zenas Biopharma Inc | Jake R. Nunn | Director | Purchase of securities on an exchange or from another person at price $ 19.00 per share. | 09 Oct 2025 | 63,158 | 1,173,395 | - | 19 | 1,200,002 | Common Stock |
| Zenas Biopharma Inc | Jake R. Nunn | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jun 2025 | 18,500 | 18,500 | - | - | Stock Option (Right to Buy) | |
| Regulus Therapeutics Inc | Jake R. Nunn | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Apr 2025 | 62,500 | 62,500 (0%) | 0% | 0 | Common Stock | |
| Zenas Biopharma Inc | Jake R. Nunn | Director | 16 Sep 2024 | 13,071,439 | 0 | - | - | Series C Convertible Preferred Stock | ||
| Zenas Biopharma Inc | Jake R. Nunn | Director | 16 Sep 2024 | 5,809,528 | 0 | - | - | Series C Convertible Preferred Stock | ||
| Zenas Biopharma Inc | Jake R. Nunn | Director | 16 Sep 2024 | 1,505,388 | 1,505,388 | - | - | Common Stock | ||
| Zenas Biopharma Inc | Jake R. Nunn | Director | 16 Sep 2024 | 669,061 | 669,061 | - | - | Common Stock | ||
| Zenas Biopharma Inc | Jake R. Nunn | Director | Purchase of securities on an exchange or from another person at price $ 17.00 per share. | 16 Sep 2024 | 441,176 | 1,946,564 | - | 17 | 7,499,992 | Common Stock |
| Zenas Biopharma Inc | Jake R. Nunn | Director | Purchase of securities on an exchange or from another person at price $ 17.00 per share. | 16 Sep 2024 | 441,176 | 1,110,237 | - | 17 | 7,499,992 | Common Stock |
| Zenas Biopharma Inc | Jake R. Nunn | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Sep 2024 | 37,000 | 37,000 | - | - | Stock Option (Right to Buy) | |
| Trevena Inc | Jake R. Nunn | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Jun 2024 | 13,700 | 13,700 | - | - | Stock Option (Right to Buy) | |
| Regulus Therapeutics Inc | Jake R. Nunn | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 May 2024 | 60,000 | 60,000 | - | - | Stock Option (Right to Buy) | |
| Regulus Therapeutics Inc | Jake R. Nunn | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 May 2024 | 30,000 | 30,000 | - | - | Stock Option (Right to Buy) | |
| Regulus Therapeutics Inc | Jake R. Nunn | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Aug 2023 | 15,000 | 15,000 | - | - | Stock Option (Right to Buy) | |
| Trevena Inc | Jake R. Nunn | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jun 2023 | 13,700 | 13,700 | - | - | Stock Option (Right to Buy) | |
| Regulus Therapeutics Inc | Jake R. Nunn | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Jun 2023 | 30,000 | 30,000 | - | - | Stock Option (Right to Buy) | |
| Trevena Inc | Jake R. Nunn | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jun 2022 | 100,000 | 100,000 | - | - | Stock Option (Right to Buy) | |
| Regulus Therapeutics Inc | Jake R. Nunn | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jun 2022 | 90,000 | 90,000 | - | - | Stock Option (Right to Buy) | |
| Trevena Inc | Jake R. Nunn | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 May 2021 | 68,577 | 68,577 | - | - | Stock Option (Right to Buy) |